Global Information
회사소개 | 문의 | 비교리스트

차세대 백신 개발을 가능하게 하는 기술

Technologies Enabling Next Generation Vaccine Development

리서치사 Frost & Sullivan
발행일 2019년 05월 상품 코드 851152
페이지 정보 영문 60 Pages
가격
US $ 4,950 ₩ 5,974,000 Web Access (Regional License) help
리서치사의 웹사이트에 로그인할 수 있는 패스워드가 발급되며, PDF를 다운로드 받는 형태로 제공됩니다. 동일 국가 내에 있는 사업장의 모든 분들이 이용할 수 있는 라이선스이며, 이용 인원수 제한은 없습니다. 텍스트 등의 PDF 내용 편집은 불가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


차세대 백신 개발을 가능하게 하는 기술 Technologies Enabling Next Generation Vaccine Development
발행일 : 2019년 05월 페이지 정보 : 영문 60 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

감염증용 차세대 백신(Next Generation Vaccine) 기술에 대해 조사했으며, 백신 전달 플랫폼, 바이러스 유사입자, 세균성·진균류 백신, 합성 백신, 바이러스 벡터 백신, 항원보강제 기술 및 백신 합성·제제·전달 플랫폼 등에 대해 분석했습니다.

제1장 주요 요약

제2장 기술 개요

제3장 새로운 백신 전달 플랫폼으로서의 나노입자

  • 나노입자가 실현되는 효율적이고 안전한 백신 전달 등

제4장 바이러스 유사입자는 유전물질을 포함하지 않는 바이러스 캡시드 단백질

  • 바이러스 유사입자는 실제 바이러스 감염을 모방 등

제5장 세균성 백신 및 진균류 백신

  • 세균성 및 진균류 백신을 위한 새로운 기술 등

제6장 합성 백신

  • 세계의 합성 백신 개발 상황 등

제7장 바이러스 벡터 백신

  • 바이러스 벡터 백신 개요 등

제8장 항원보강제 기술

  • 항원보강제로서의 새로운 지방질 제제 등

제9장 백신 합성, 제제 및 전달 플랫폼

  • 백신 합성, 제제 및 전달 플랫폼 개요 등

제10장 성장 기회와 추천 행동(CTA)

  • 성장 기회 1 : 인플루엔자 백신
  • 성장 기회 2 : 매개체 감염 질환
  • 성장 기회 3 : 백신 전달 기술
  • 성공 및 성장을 위한 전략적 원칙

제11장 주요 산업 기업

LSH 19.06.03

Upcoming Vaccine Technologies for Infectious Diseases

Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ( inorganic and polymeric). The biological nanoparticles subsection overlaps with virus-like particles that has been separately addressed.

Virus-Like Particles: Virus-Like Particles are biological nanoparticles having size of around 20-100 nm. Due to the repetitive nature, viral capsid proteins have tendency to self-assemble. Lack of genetic material makes them non-replicative and hence safe vaccines. Therefore, VLPs are gaining a lot of attractions from vaccine development point of view.

Bacterial and fungal vaccines: This part discusses upcoming vaccines which can protect against multiple bacterial and fungal infections, toxoid vaccines, neutralizing antibodies and new technologies like carbohydrate-conjugate vaccines, surface antigen vaccines etc.

Synthetic vaccines: The segment of synthetic vaccines talks about the short, long and synthetic peptide vaccines against viral and bacterial diseases, innovative T cell stimulating immunogens and fusion proteins.

Viral vector-based vaccines: It covers genetically modified viral vectors which are engineered to make replication incompetent by deletion of essential genes or highly attenuated viral vectors that lack pathogenic genes.

Adjuvant technology: Unique lipid-based adjuvants, oil-in-water adjuvants, plant-derived adjuvants, synthetic and immune-cell-receptor based adjuvants as well as virosomes (derived from viral proteins) are reviewed here.

Vaccine synthesis, formulation and delivery platforms: This section partially overlaps with virus-based vaccine delivery platforms like virosomes, synthetic and modified-viral platforms, cell-free protein synthesis and gene delivery methods and proprietary cell lines used for vaccine production.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Research Scope: Vaccine Technologies Under Development Phase
  • 1.2. Analysis Framework: Frost & Sullivan Core Value
  • 1.3. Research Methodology: Five Steps Toward Success
  • 1.4. Key Findings of Global Vaccine Technology Development

2.0. TECHNOLOGY SNAPSHOT

  • 2.1. Research Scope: Current Status and Challenges of Vaccine Development
  • 2.2. Technologies Transforming Next-generation Vaccines

3.0. NANOPARTICLES AS NOVEL VACCINE DELIVERY PLATFORMS

  • 3.1. Nanoparticles Enable Efficient and Safe Vaccine Delivery
  • 3.2. Self-assembling Nanoparticles of Biological Origin
  • 3.3. Polymeric and Inorganic Nanoparticles for Vaccine Delivery

4.0. VIRUS-LIKE PARTICLES ARE SELF-ASSEMBLING VIRUS CAPSID PROTEINS WITHOUT THE GENETIC MATERIAL

  • 4.1. Virus-like Particles Mimic The Real Viral Infection
  • 4.2. Landscape of VLP-based Vaccines, Global, 2019
  • 4.3. Influenza Shares A Major Portion of VLP-based Vaccines
  • 4.4. Multiple Adaptations of VLP Technology for Vaccine Development
  • 4.5. Plant Leaves Producing A Wide Variety of VLPs

5.0. BACTERIAL AND FUNGAL VACCINES

  • 5.1. Emerging Technologies for Bacterial and Fungal Vaccines
  • 5.2. Emerging Bacterial and Fungal Vaccines, Global, 2019
  • 5.3. New Strategies for Bacterial and Fungal Vaccines
  • 5.4. Novel Vaccines & Therapeutics for Emerging Infectious Diseases
  • 5.5. Multi-protein Complex-based Bacterial Vaccines
  • 5.6. Carbohydrates-based or Conjugate Vaccines

6.0. SYNTHETIC VACCINES

  • 6.1. Development Status of Synthetic Vaccines, Global, 2019
  • 6.2. Peptides-based Vaccine Technologies
  • 6.3. Genetically Modified Vaccines for HIV and Streptococci

7.0. VIRAL VECTOR-BASED VACCINES

  • 7.1. Overview of Viral Vector-based Vaccines
  • 7.2. Summary of Developing Viral Vector Vaccine Technology, Global, 2019
  • 7.3. Diverse Replication-incompetent Viral Vaccines
  • 7.4. Replication-incompetent Viruses with Nasal Spray Formulation
  • 7.5. Live Attenuated Influenza Vaccines with Nasal Formulation
  • 7.6. Viral Vector Vaccines for Serious Human Diseases
  • Flu vaccine based on regions of limited variability

8.0. ADJUVANT TECHNOLOGY

  • 8.1. Novel Lipid Formulations as Adjuvant
  • 8.2. Oil-in-water Nanoemulsion and Saponin-based Adjuvants
  • 8.3. Toll-like Receptor-based Adjuvants

9.0. VACCINE SYNTHESIS, FORMULATION, AND DELIVERY PLATFORMS

  • 9.1. Synopsis of Vaccine Synthesis, Formulation Delivery Platforms
  • 9.2. Cell-free and Cell-based Vaccine Synthesis Platforms
  • 9.3. Diverse Vaccine Formulation Technologies
  • 9.4. Needle-less Solid Dose Vaccine Delivery Formulation and Device
  • 9.5. Gold Nanoparticles and Applications in Vaccine Delivery
  • 9.6. Nanopatch, Recombinant Protein and Lipid-based Carriers

10. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • 10.1. Growth Opportunity 1: Influenza Vaccines
  • 10.2. Growth Opportunity 2: Vaccines for Vector Borne Viral Diseases
  • 10.3. Growth Opportunity 3: Vaccine Delivery Technologies
  • 10.4. Strategic Imperatives for Success and Growth

11. KEY INDUSTRY INFLUENCERS

  • 11.1. Industry Interactions
  • Legal Disclaimer
Back to Top
전화 문의
F A Q